Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.50 |
| ▸ | HRH1 | P35367 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17033077 | 0.81 | HRH3 (0.44) | HRH3HRH1ALDH1A1LMNATAAR1 | |
| SCHEMBL27909802 | 0.78 | HRH1 (0.50) | HRH3HRH1L3MBTL1ALDH1A1LMNA | |
| SCHEMBL20825349 | 0.75 | HRH1 (0.47) | HRH3HRH1L3MBTL1ALDH1A1LMNA | |
| SCHEMBL230753 | 0.75 | HRH1 (0.73) | HRH3HRH1ALDH1A1LMNATAAR1 | |
| SCHEMBL29485678 | 0.75 | HRH1 (0.73) | HRH3HRH1ALDH1A1LMNATAAR1 | |
| Bromide SCHEMBL28641396 | 0.73 | HRH1 (0.70) | HRH3HRH1ALDH1A1LMNATAAR1 | |
| SCHEMBL16724857 | 0.72 | HRH1 (0.57) | HRH3HRH1L3MBTL1ALDH1A1LMNA | |
| SCHEMBL29583126 | 0.71 | — | — | |
| SCHEMBL56199 | 0.71 | — | — | |
| SCHEMBL10527 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2906246-B1 | VEGF NEUTRALIZING PRODRUGS COMPRISING RANIBIZUMAB FOR THE TREATMENT OF OCULAR CONDITIONS CHARACTERIZED BY OCULAR NEOVASCULARIZATION | ASCENDIS PHARMA OPHTHALMOLOGY DIV A/S (DK) | 2023-07-26 | — | — | EP | disclosed |